US 12384854
Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
granted A61KA61K2039/505A61K2039/545
Quick answer
US patent 12384854 (Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema) held by Takeda Pharmaceutical Company Limited expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K2039/505, A61K2039/545, A61P, A61P7/10